nach oben

Erschienen in:

01.03.2023 | RESEARCH ARTICLES

Comparative Analysis of Cell Senescence Induced by the Chemotherapeutic Agents Doxorubicin, Cisplatin and Arsenic Trioxide in Human Myoblasts MB135

verfasst von: M. A. Chelombitko, G. V. Morgunova, N. Yu. Strochkova, R. A. Zinovkin, A. N. Pavlyuchenkova, N. D. Kondratenko, K. G. Lyamzaev

Erschienen in: Advances in Gerontology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Genotoxic and cytotoxic drugs, widely used in anticancer therapy, target proliferating cells and induce cell death through a variety of cell cycle-dependent mechanisms. The mechanisms of the delayed toxicity induced by chemotherapy are not fully understood. The accumulation of senescent cells may underlie some of the mechanisms for the development of late adverse effects of chemotherapy on muscle tissue. Cellular models are necessary for the development of therapeutic approaches to these side effects. In our study we used human immortalized myoblast MB135 to optimize the protocol for obtaining the senescent phenotype of muscle cells under the influence of chemotherapeutic drugs such as doxorubicin, cisplatin and arsenic trioxide (As₂O₃). We evaluated the dynamics of changes in senescence proteins pRb, p21 and p53 and SASP-associated proteins such as TNF, IL-1b, IL-6, IL-8, CXCL2, GDF15 using Western blot, RT-PCR and ELISA. Cell senescence was confirmed by the measurement of cell senescence index by flow cytometry after 7 days of exposure to chemotherapeutic agents. The obtained results indicate that all three investigated chemotherapeutic compounds induce the appearance of senescence markers, but the dynamics of these changes are somewhat different for them, which may reflect differences in the mechanisms of senescence phenotype induction.

Schünemann, M., Anker, S.D., and Rauchhaus, M., Cancer fatigue syndrome reflects clinically non-overt heart failure: An approach towards onco-cardiology, Nat. Clin. Pract. Oncol., 2008, vol. 5, no. 11, pp. 632–633.CrossRefPubMed

Hudson, M.M., Ness, K.K., Gurney, J.G., Mulrooney, D.A., Chemaitilly, W., Krull, K.R., Green, D.M., Armstrong, G.T., Nottage, K.A., Jones, K.E., Sklar, C.A., Srivastava, D.K., and Robison, L.L., Clinical ascertainment of health outcomes among adults treated for childhood cancer, J. Am. Med. Assoc., 2013, vol. 309, no. 22, pp. 2371–2381.CrossRef

Chen, M.S., Lee, R.T., and Garbern, J.C., Senescence mechanisms and targets in the heart, Cardiovasc. Res., 2022, vol. 118, no. 5, pp. 1173–1187.CrossRefPubMed

Mehdizadeh, M., Aguilar, M., Thorin, E., Ferbeyre, G., and Nattel, S., The role of cellular senescence in cardiac disease: Basic biology and clinical relevance, Nat. Rev. Cardiol., 2022, vol. 19, no. 4, pp. 250–264.CrossRefPubMed

Vizioli, M.G., Liu, T., Miller, K.N., Robertson, N.A., Gilroy, K., Lagnado, A.B., Perez-Garcia, A., Kiourtis, C., Dasgupta, N., Lei, X., Kruger, P.J., Nixon, C., Clark, W., Jurk, D., Bird, T.G., Passos, J.F., Berger, S.L., Dou, Z., and Adams, P.D., Mitochondria-to-nucleus retrograde signaling drives formation of cytoplasmic chromatin and inflammation in senescence, Genes Dev., 2020, vol. 34, nos. 5–6, pp. 428–445.CrossRefPubMedPubMedCentral

Singh, P., Sharma, R., McElhanon, K., Allen, C.D., Megyesi, J.K., Benes, H., and Singh, S.P., Sulforaphane protects the heart from doxorubicin-induced toxicity, Free Radic. Biol. Med., 2015, vol. 86, pp. 90–101.CrossRefPubMedPubMedCentral

Hiensch, A.E., Bolam, K.A., Mijwel, S., Jeneson, J.A.L., Huitema, A.D.R., Kranenburg, O., van der Wall, E., Rundqvist, H., Wengstrom, Y., and May, A.M., Doxorubicin-induced skeletal muscle atrophy: Elucidating the underlying molecular pathways, Acta Physiol., 2020, vol. 229, no. 2, р. e13400.

Dugbartey, G.J., Peppone, L.J., and de Graaf, I.A.M., An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures, Toxicology, 2016, vol. 371, pp. 58–66.CrossRefPubMed

Conte, E., Bresciani, E., Rizzi, L., Cappellari, O., De Luca, A., Torsello, A., and Liantonio, A., Cisplatin-induced skeletal muscle dysfunction: Mechanisms and counteracting therapeutic strategies, Int. J. Mol. Sci., 2020, vol. 21, no. 4, p. 1242.CrossRefPubMedPubMedCentral

10.

Andreou, C. and Matsakas, A., Current insights into cellular senescence and myotoxicity induced by doxorubicin: The role of exercise and growth factors, Int. J. Sports Med., 2022, vol. 43, no. 13, pp. 1084–1096.CrossRefPubMed

11.

Echaniz-Laguna, A., Benoilid, A., Vinzio, S., Fornecker, L.M., Lannes, B., Goullé, J.P., Broly, F., and de Camaret, B., Mitochondrial myopathy caused by arsenic trioxide therapy, Blood, 2012, vol. 119, no. 18, pp. 4272–4274.CrossRefPubMed

12.

Yen, Y.P., Tsai, K.S., Chen, Y.W., Huang, C.F., Yang, R.S., and Liu, S.H., Arsenic inhibits myogenic differentiation and muscle regeneration, Environ. Health Perspect., 2010, vol. 118, no. 7, pp. 949–956.CrossRefPubMedPubMedCentral

13.

Piegari, E., De Angelis, A., Cappetta, D., Russo, R., Esposito, G., Costantino, S., Graiani, G., Frati, C., Prezioso, L., Berrino, L., Urbanek, K., Quaini, F., and Rossi, F., Doxorubicin induces senescence and impairs function of human cardiac progenitor cells, Basic Res. Cardiol., 2013, vol. 108, no. 2, p. 334.CrossRefPubMed

14.

Demaria, M., O’Leary, M.N., Chang, J., Shao, L., Liu, S., Alimirah, F., Koenig, K., Le, C., Mitin, N., Deal, A.M., Alston, S., Academia, E.C., Kilmarx, S., Valdovinos, A., Wang, B., de Bruin, A., Kennedy, B.K., Melov, S., Zhou, D., Sharpless, N.E., Muss, H., and Campisi, J., Cellular senescence promotes adverse effects of chemotherapy and cancer relapse, Cancer Discov., 2017, vol. 7, no. 2, pp. 165–176.CrossRefPubMed

15.

Wang, B., Kohli, J., and Demaria, M., Senescent cells in cancer therapy: Friends or foes?, Trends Cancer Res., 2020, vol. 6, no. 10, pp. 838–857.CrossRef

16.

Jagannathan, S., Shadle, S.C., Resnick, R., Snider, L., Tawil, R.N., van der Maarel, S.M., Bradley, R.K., and Tapscott, S.J., Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells, Hum. Mol. Genet., 2016, vol. 25, no. 20, pp. 4419–4431.PubMedPubMedCentral

17.

Malavolta, M., Giacconi, R., Piacenza, F., Strizzi, S., Cardelli, M., Bigossi, G., Marcozzi, S., Tiano, L., Marcheggiani, F., Matacchione, G., Giuliani, A., Olivieri, F., Crivellari, I., Beltrami, A.P., Serra, A., Demaria, M., and Provinciali, M., Simple detection of unstained live senescent cells with imaging flow cytometry, Cells, 2022, vol. 11, no. 16, р. 2506.CrossRefPubMedPubMedCentral

18.

Brookes, S., Gagrica, S., Sanij, E., Rowe, J., Gregory, F.J., Hara, E., and Peters, G., Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence, Cell Cycle, 2015, vol. 14, no. 8, pp. 1164–1173.CrossRefPubMedPubMedCentral

19.

Gao, Y., Wu, T., Tang, X., Wen, J., Zhang, Y., Zhang, J., and Wang, S., Increased cellular senescence in doxorubicin-induced murine ovarian injury: Effect of senolytics, Geroscience, 2023, vol. 45, no. 3, pp. 1775–1790.CrossRefPubMedPubMedCentral

20.

Efferth, T., Konkimalla, V.B., Wang, Y.F., Sauerbrey, A., Meinhardt, S., Zintl, F., Mattern, J., and Volm, M., Prediction of broad spectrum resistance of tumors towards anticancer drugs, Clin. Cancer Res., 2008, vol. 14, no. 8, pp. 2405–2412.CrossRefPubMed

21.

Jurisicova, A., Lee, H.J., D’Estaing, S.G., Tilly, J., and Perez, G.I., Molecular requirements for doxorubicin-mediated death in murine oocytes, Cell Death Differ., 2006, vol. 13, no. 9, pp. 1466–1474.CrossRefPubMed

22.

Morgan, S., Lopes, F., Gourley, C., Anderson, R.A., and Spears, N., Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin, PLoS One, 2013, vol. 8, no. 7, р. e70117.ADSCrossRefPubMedPubMedCentral

23.

Gonzalez, V.M., Fuertes, M.A., Alonso, C., and Perez, J.M., Is cisplatin-induced cell death always produced by apoptosis?, Mol. Pharmacol., 2001, vol. 59, no. 4, pp. 657–663.CrossRefPubMed

24.

Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D., and Dou, Q.P., Novel metals and metal complexes as platforms for cancer therapy, Curr. Pharm. Des., 2010, vol. 16, no. 16, pp. 1813–1825.CrossRefPubMedPubMedCentral

25.

Matsumoto, C., Sekine, H., Zhang, N., Mogami, S., Fujitsuka, N., and Takeda, H., Role of p53 in cisplatin-induced myotube atrophy, Int. J. Mol. Sci., 2023, vol. 24, no. 11, р. 9176.CrossRefPubMedPubMedCentral

26.

Zhou, L., Lu, R., Huang, C., and Lin, D., Taurine protects C2C12 myoblasts from impaired cell proliferation and myotube differentiation under cisplatin-induced ROS exposure, Front. Mol. Biosci., 2021, vol. 8, р. 685362.CrossRefPubMedPubMedCentral

27.

Dawood, M., Hamdoun, S., and Efferth, T., Multifactorial modes of action of arsenic trioxide in cancer cells as analyzed by classical and network pharmacology, Front. Pharmacol., 2018, vol. 9, р. 143.CrossRefPubMedPubMedCentral

28.

Sugihara, H., Teramoto, N., Yamanouchi, K., Matsuwaki, T., and Nishihara, M., Oxidative stress-mediated senescence in mesenchymal progenitor cells causes the loss of their fibro/adipogenic potential and abrogates myoblast fusion, Aging, 2018, vol. 10, no. 4, pp. 747–763.CrossRefPubMedPubMedCentral

29.

He, Y., Xie, W., Li, H., Jin, H., Zhang, Y., and Li, Y., Cellular senescence in sarcopenia: Possible mechanisms and therapeutic potential, Front. Cell Dev. Biol., 2021, vol. 9, р. 793088.CrossRefPubMed

30.

Campisi, J., Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors, Cell, 2005, vol. 120, no. 4, pp. 513–522.CrossRefPubMed

Titel: Comparative Analysis of Cell Senescence Induced by the Chemotherapeutic Agents Doxorubicin, Cisplatin and Arsenic Trioxide in Human Myoblasts MB135
verfasst von: M. A. Chelombitko
G. V. Morgunova
N. Yu. Strochkova
R. A. Zinovkin
A. N. Pavlyuchenkova
N. D. Kondratenko
K. G. Lyamzaev
Publikationsdatum: 01.03.2023
Verlag: Pleiades Publishing
Erschienen in: Advances in Gerontology / Ausgabe 1/2023
Print ISSN: 2079-0570
Elektronische ISSN: 2079-0589
DOI: https://doi.org/10.1134/S2079057024600010

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Comparative Analysis of Cell Senescence Induced by the Chemotherapeutic Agents Doxorubicin, Cisplatin and Arsenic Trioxide in Human Myoblasts MB135

Abstract

Leitlinien kompakt für die Allgemeinmedizin

Facharzt-Training Allgemeinmedizin

Neu im Fachgebiet Allgemeinmedizin

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Wie der Klimawandel gefährliche Pilzinfektionen begünstigt

So wirken verschiedene Alkoholika auf den Blutdruck

Das sind die führenden Symptome junger Darmkrebspatienten

Update Allgemeinmedizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Gerontology in the 21st Century: From Failures to Advances. Hopefully

Mitochondrial Antioxidant SkQ1 Affects the GABAergic but Not the Glutamatergic System in the Hippocampus of Wistar and Senescence Accelerated OXYS Rats

New Frailty Index Approach Predicts COVID-19 Mortality Risk

Age-Related Changes in the Metabolomic Composition of Macaque (Macaca fascicularis) Ocular Tissues

Reductionism and Holism in the History of Aging and Longevity Research: Does the Whole Have Parts? Part 1. The Building of Reductionism

Leitlinien kompakt für die Allgemeinmedizin

Facharzt-Training Allgemeinmedizin

Neu im Fachgebiet Allgemeinmedizin

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Wie der Klimawandel gefährliche Pilzinfektionen begünstigt

So wirken verschiedene Alkoholika auf den Blutdruck

Das sind die führenden Symptome junger Darmkrebspatienten

Update Allgemeinmedizin